
    
      This is A multi-center, randomized, double-blind, comparative clinical trial.

      The primary objective is to evaluate whether the clinical efficacy of QL1206 and Xgeva® are
      similar in patients with bone metastases from solid tumors.

      The secondary objective are to evaluate whether the clinical safety and immunogenicity of
      QL1206 and Xgeva® are similar in patients with bone metastases from solid tumors.
    
  